Clinical trials: Muscle-invasive Bladder Cancer
Bladder Cancer
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
The investigators aim to investigate a possible role for radiotherapy in good prognosis bladder cancer patients has been identified as a possible alternative to cystectomy, especially for patients non-eligible for surgery but has…
- Trial name
- NCT06310369
- Testing
- radiation therapy
- Volunteers
- 50 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer
Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure
Patients with urothelial high risk non-muscle invasive bladder cancer patients will be treated with intravesical electromotive drug administration/mitomycin (EMDA/MMC) after bacillus Calmette-Guerin (BCG) failure.
- Trial name
- NCT04311580
- Testing
- intravesical electromotive administration of mitomycin
- Volunteers
- 52 people
- Sponsor
- University of Rome Tor Vergata
Bladder Cancer
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Neoadjuvant chemotherapy plus radical cystectomy is the standard if care for cisplatin-eligible patients with MIBC. Developments in the last two decades suggest that bladder sparing therapy may be a valuable alternative to…
- Trial name
- NCT05531123
- Testing
- Tislelizumab, gemcitabine and cisplatin, Modified hypofractionation
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fudan University
Muscle-Invasive Bladder Carcinoma
AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
AURORAX-0093A (AUR93A) is a pilot cohort observational study that will explore the use of urine and plasma glycosaminoglycans (GAGs) to prognosticate muscle-invasive bladder cancer (MIBC) patients elected for neo-adjuvant…
- Trial name
- AUR93A (NCT05028660)
- Testing
- GAG score
- Where
- 5 sites in Denmark, Italy and 1 more
- Volunteers
- 43 people
- Sponsor
- Elypta
Bladder Cancer
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer
Open, multicentre, phase II trial of atezolizumab with concurrent normofractionated radiotherapy in patients with localized muscle-invasive bladder cancer treated with a selective multimodality bladder conservative approach.
- Trial name
- NCT04186013
- Testing
- Atezolizumab Injection [Tecentriq], External Beam Radiation Therapy (EBRT)
- Where
- 10 sites in Spain
- Volunteers
- 39 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
This phase I/II trial is studying the side effects of giving paclitaxel together with radiation therapy with or without trastuzumab and to see how well it works to kill any remaining tumor cells in patients who have undergone…
- Conditions
- Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
- Trial name
- NCT00238420
- Testing
- Paclitaxel, Radiation Therapy, Trastuzumab
- Where
- 184 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)